Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

DOI: 10.1530/eje.0.1460583
European Journal of Endocrinology, Vol 146, Issue 4, 583-589
Copyright © 2002 by European Society of Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nativelle-Serpentini, C
Right arrow Articles by Sourdaine, P
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nativelle-Serpentini, C
Right arrow Articles by Sourdaine, P
Articles

Aromatase and breast cancer: W39R, an inactive protein

C Nativelle-Serpentini, S Lambard, GE Seralini, and P Sourdaine

Institut de Biochemie et Biologie Appliquee, EA 2608, Laboratoire de Biochimie et de Biologie Moleculaire, Universite de Caen, Esplanade de la Paix, 14032 Caen Cedex, France.

BACKGROUND: Aromatase (CYP19) catalyzes the conversion of androgens into estrogens. It is in particular involved in development, reproduction and breast cancer. One of its polymorphisms, W39R localized in the N-terminal region of CYP19, significantly decreases breast cancer risk among Japanese women and was chosen for this study. In this work, we studied the structure-function relationships between W39R polymorphism and CYP19 enzyme activity. OBJECTIVE: To examine the kinetic properties of the mutant W39R recombinant protein in transfected human cells devoid of steroidogenic activity. METHODS: Expression vectors for the wild-type or the mutated R39 aromatase were transiently transfected into E293 human embryonal kidney cells. The conversions of androstenedione to estrone and of testosterone and nortestosterone to 17beta-estradiol were assayed by RIA. Expression of recombinant cDNAs was analyzed by semi-quantitative RT-PCR and immunoblotting. RESULTS: W39R recombinant protein was devoid of aromatase activity whatever the substrate used. This absence of activity was not due to the lack of expression of the recombinant enzyme since the mRNA and protein were detected. CONCLUSION: Our present in vitro study shows that the R39 mutant is unable to synthesize estrogens. This work provides a novel observation, being consistent with the fact that Japanese women with the variant allele (arg) have significantly lower risk of developing a breast tumor.


This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
M. H. Tao, Q. Cai, Z.-F. Zhang, W.-H. Xu, N. Kataoka, W. Wen, Y.-B. Xiang, W. Zheng, and X. O. Shu
Polymorphisms in the CYP19A1 (Aromatase) Gene and Endometrial Cancer Risk in Chinese Women
Cancer Epidemiol. Biomarkers Prev., May 1, 2007; 16(5): 943 - 949.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. X. Ma, A. A. Adjei, O. E. Salavaggione, J. Coronel, L. Pelleymounter, L. Wang, B. W. Eckloff, D. Schaid, E. D. Wieben, A. A. Adjei, et al.
Human Aromatase: Gene Resequencing and Functional Genomics
Cancer Res., December 1, 2005; 65(23): 11071 - 11082.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
C. A. Haiman, D. O. Stram, M. C. Pike, L. N. Kolonel, N. P. Burtt, D. Altshuler, J. Hirschhorn, and B. E. Henderson
A comprehensive haplotype analysis of CYP19 and breast cancer risk: the Multiethnic Cohort
Hum. Mol. Genet., October 16, 2003; 12(20): 2679 - 2692.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 European Society of Endocrinology.